Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CVRX 
CVRx Inc (CVRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CVRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.83
1 Year Target Price $10.83
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 6.02% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 181.75M USD | Price to earnings Ratio - | 1Y Target Price 10.83 |
Price to earnings Ratio - | 1Y Target Price 10.83 | ||
Volume (30-day avg) 7 | Beta 1.22 | 52 Weeks Range 4.30 - 18.55 | Updated Date 09/17/2025 |
52 Weeks Range 4.30 - 18.55 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -95.61% | Operating Margin (TTM) -105.79% |
Management Effectiveness
Return on Assets (TTM) -29.63% | Return on Equity (TTM) -92.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 136723563 | Price to Sales(TTM) 3.33 |
Enterprise Value 136723563 | Price to Sales(TTM) 3.33 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA -1.31 | Shares Outstanding 26072600 | Shares Floating 17964142 |
Shares Outstanding 26072600 | Shares Floating 17964142 | ||
Percent Insiders 4.31 | Percent Institutions 67.71 |
Upturn AI SWOT
CVRx Inc
Company Overview
History and Background
CVRx, Inc. is a medical device company founded in 2000. It focuses on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with heart failure and hypertension. The company has evolved from initial research and development to commercializing its Barostim System.
Core Business Areas
- Neuromodulation Therapies: CVRx develops and markets neuromodulation devices designed to improve cardiovascular function. Their main product is the Barostim System.
Leadership and Structure
CVRx is led by a management team with experience in medical devices and cardiovascular therapies. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Barostim System: The Barostim System is CVRx's flagship product. It is an implantable device that delivers electrical stimulation to the baroreceptors in the carotid artery, which in turn signals the brain to reduce sympathetic nerve activity and improve cardiovascular function. It is used to treat heart failure and hypertension. Market share data is evolving; specifics are difficult to obtain. Competitors include companies offering other neuromodulation therapies and traditional heart failure treatments. There is no direct competitor for this exact technology but companies like Medtronic (MDT) and Abbott (ABT) are competitors in providing treatment for these patients.
Market Dynamics
Industry Overview
The medical device industry, specifically the cardiovascular device segment, is characterized by ongoing innovation and increasing adoption of minimally invasive procedures. Demand is driven by an aging population and rising prevalence of heart failure and hypertension.
Positioning
CVRx is positioned as a leader in neuromodulation therapies for cardiovascular diseases. Its Barostim System offers a unique approach to treating heart failure and hypertension, potentially providing benefits not achieved with traditional therapies.
Total Addressable Market (TAM)
The TAM for heart failure and hypertension therapies is substantial, estimated to be in the billions of dollars globally. CVRx is targeting a specific segment within this market, focusing on patients who are not adequately managed with existing treatments.
Upturn SWOT Analysis
Strengths
- Innovative technology (Barostim)
- First-mover advantage in neuromodulation for heart failure and hypertension
- Strong intellectual property portfolio
- Clinical evidence supporting the efficacy of Barostim
Weaknesses
- Limited market penetration
- High cost of device and implantation procedure
- Dependence on a single product (Barostim)
- Relatively small size compared to larger medical device companies
Opportunities
- Expanding indications for Barostim
- Increasing awareness and adoption of neuromodulation therapies
- Strategic partnerships with hospitals and healthcare providers
- Geographic expansion into new markets
Threats
- Competition from established medical device companies
- Reimbursement challenges from payers
- Potential for technological advancements by competitors
- Regulatory risks associated with medical devices
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Abbott (ABT)
- Boston Scientific (BSX)
Competitive Landscape
CVRx's competitive advantage lies in its unique neuromodulation technology. However, it faces strong competition from larger, well-established medical device companies with broader product portfolios and greater resources.
Growth Trajectory and Initiatives
Historical Growth: CVRx's historical growth is tied to the adoption rate of the Barostim System and expansion into new markets.
Future Projections: Future growth projections depend on market penetration, regulatory approvals, and competitive landscape changes. Analyst estimates can be found on financial news websites.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, conducting clinical trials to support new indications, and seeking regulatory approvals in new geographies.
Summary
CVRx is a medical device company with an innovative neuromodulation technology for heart failure and hypertension. While the Barostim system offers a unique approach, the company faces challenges related to market penetration, reimbursement, and competition from larger players. To be successful, CVRx must focus on expanding its market reach, securing favorable reimbursement policies, and continuing to innovate in the field of neuromodulation. Success hinges on the continued demonstration of clinical efficacy and cost-effectiveness of the Barostim System.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news outlets
- Analyst reports
- Clinical trial publications
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise. Financial performance is subject to change. This assessment is based on publicly available data as of the date of generation and is subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CVRx Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2021-06-30 | President, CEO & Director Mr. Kevin Hykes | ||
Sector Healthcare | Industry Medical Devices | Full time employees 206 | Website https://www.cvrx.com |
Full time employees 206 | Website https://www.cvrx.com | ||
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.